|Articles|April 1, 2002

Your Voice

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Infliximab, steroids may outperform anakinra for IVIG-resistant MIS-C | Image Credit: © Bernard Chantal - stock.adobe.com

Infliximab, steroids may outperform anakinra for IVIG-resistant MIS-C

ByMorgan Ebert, Executive Editor

August 19th 2026

FDA accepts ecopipam NDA with priority review for pediatric Tourette syndrome

FDA accepts ecopipam NDA with priority review for pediatric Tourette syndrome

ByMorgan Ebert, Executive Editor

August 19th 2026

Managing AD Flares and Debunking the Food Allergy Myth

ByLisa Swanson, MD, Ada West Dermatology

August 19th 2026

Misdiagnosis Pitfalls and the Hidden Consequences of Uncontrolled AD

ByLisa Swanson, MD, Ada West Dermatology

August 19th 2026

Early antiviral therapy linked to 81% lower influenza hospitalization risk in children | Image Credit: © pingpao - stock.adobe.com.

Early antiviral therapy linked to 81% lower influenza hospitalization risk in children

ByMorgan Ebert, Executive Editor

August 18th 2026

Trending on Contemporary Pediatrics

FDA accepts ecopipam NDA with priority review for pediatric Tourette syndrome

Infliximab, steroids may outperform anakinra for IVIG-resistant MIS-C

Managing AD Flares and Debunking the Food Allergy Myth

Early antiviral therapy linked to 81% lower influenza hospitalization risk in children

Social media linked to riskier product use in teens